Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00218218 · ClinicalTrials.gov registry record · Phase 2
Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia
A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT00218218 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 48 participants.
The verdict
NCT00218218, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
Individuals with schizophrenia are three times as likely to smoke cigarettes as individuals without schizophrenia. While a great deal of research has been focused on smoking cessation programs for healthy individuals, little attention has been directed towards developing an effective smoking cessation treatment for schizophrenics. This project will evaluate the effects of 0, 21 and 42 mg transdermal nicotine on smoking, urge to smoke, and nicotine withdrawal symptoms after 5 hrs abstinence in smokers with schizophrenia and heavy-smoking non-psychiatric control smokers.
Interventions
- DRUG Transdermal Nicotine Patch
- DRUG placebo patch
- DRUG 21 mg transdermal nicotine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2002-06 |
| Est. Completion | 2005-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00218218
The ClinicalTrials.gov registry entry for NCT00218218 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Transdermal Nicotine Patch is the first listed.
NCT00218218 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00218218 about?
NCT00218218 is a clinical study titled "Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia". Individuals with schizophrenia are three times as likely to smoke cigarettes as individuals without schizophrenia. While a great deal of research has been focused on smoking cessation programs for healthy individuals, little attention has been directed towards developing an effective smoking cessati...
What is the current status of trial NCT00218218?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2002-06. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00218218?
The interventions under investigation include: Transdermal Nicotine Patch (DRUG), placebo patch (DRUG), 21 mg transdermal nicotine (DRUG).
Who is sponsoring clinical trial NCT00218218?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.